Report Overview
Report Summary
Eternity Insights has published a new study on Global Blood Cancer Drugs Market focusing on key segments By Type (Blood Chemotherapy Drugs, Blood Targeted Therapy Drugs, Other), By Application (Leukemia, Lymphoma, Multiple Myeloma, Other), and by region. This deep-dive research report highlights the market and competitive intelligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Blood Cancer Drugs Market.
The report considers 2018-2020 as historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the market drivers, challenges, and trends to accurately map the market scenario and competition. Moreover, key insights related to market having direct impact on the market will also be covered.
Blood Cancer Drugs Market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
Global Blood Cancer Drugs Market Size, 2018-2028 (USD Million)
To learn more about this report
Global Blood Cancer Drugs Market Segmentation:
Blood Cancer Drugs Market, By Type
- Blood Chemotherapy Drugs
- Blood Targeted Therapy Drugs
- Other
Blood Cancer Drugs Market, By Application
- Leukemia
- lymphoma
- Multiple Myeloma
- Other
To learn more about this report
Geographically, the market is categorized in to five regions as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region dominates the global Blood Cancer Drugs market in terms of demand generation. The Blood Cancer Drugs market in Asia Pacific region is expected to grow at significantly high growth rate. The regional market is further sub-segmented and analyzed at granular level across key countries. The report will include market size and forecast for Blood Cancer Drugs market for the below-listed countries across each region.
North America (U.S. and Canada), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific region); Latin America (Brazil, Mexico, and rest of the Latin America); Middle East and Africa (GCC, South Africa, and Rest of the Middle East and Africa).
Global Blood Cancer Drugs Market Taxonomy:
To learn more about this report
Global Blood Cancer Drugs Market Competitive Landscape
The global Blood Cancer Drugs market analysis report covers detailed analysis of the competitive scenario across globe. The report includes profiles of leading players covering below details
- Company Overview
- Financial Analysis
- Product Portfolio Analysis
- Strategic Overview
- SWOT Analysis
List of Companies Profiled in the report:
- Amgen
- AstraZeneca PLC
- Astellas Pharma
- Bayer AG
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly
- F.Hoffmann-La Roche
- Johnson & Johnson
- Novartis
- Pfizer
- Takeda Pharmaceutical Company Ltd
- AbbVie
- Other Players of Specific Interest can be added based on the requirement
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Blood Chemotherapy Drugs, Blood Targeted Therapy Drugs, Other |
| By Application Outlook |
Leukemia, lymphoma, Multiple Myeloma, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Amgen, AstraZeneca PLC, Astellas Pharma, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly, F.Hoffmann-La Roche, Johnson & Johnson, Novartis, Pfizer, Takeda Pharmaceutical Company Ltd, AbbVie |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Benefits to the stakeholders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
Table Of Contents
Table Of Contents
Table of Contents
1 Blood Cancer Drugs Market Overview
1.1 Blood Cancer Drugs Product Overview
1.2 Blood Cancer Drugs Market Segment by Type
1.2.1 Blood Chemotherapy Drugs
1.2.2 Blood Targeted Therapy Drugs
1.3 Global Blood Cancer Drugs Market Size by Type
1.3.1 Global Blood Cancer Drugs Sales and Growth by Type
1.3.2 Global Blood Cancer Drugs Sales and Market Share by Type (2014-2019)
1.3.3 Global Blood Cancer Drugs Revenue and Market Share by Type (2014-2019)
1.3.4 Global Blood Cancer Drugs Price by Type (2014-2019)
2 Global Blood Cancer Drugs Market Competition by Company
2.1 Global Blood Cancer Drugs Sales and Market Share by Company (2014-2019)
2.2 Global Blood Cancer Drugs Revenue and Share by Company (2014-2019)
2.3 Global Blood Cancer Drugs Price by Company (2014-2019)
2.4 Global Top Players Blood Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Types
2.5 Blood Cancer Drugs Market Competitive Situation and Trends
2.5.1 Blood Cancer Drugs Market Concentration Rate
2.5.2 Global Blood Cancer Drugs Market Share of Top 5 and Top 10 Players
2.5.3 Mergers & Acquisitions, Expansion
3 Blood Cancer Drugs Company Profiles and Sales Data
3.1 Amgen,
3.1.1 Company Basic Information, Manufacturing Base and Competitors
3.1.2 Blood Cancer Drugs Product Category, Application and Specification
3.1.3 Amgen, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.1.4 Main Business Overview
3.2 AstraZeneca PLC,
3.2.1 Company Basic Information, Manufacturing Base and Competitors
3.2.2 Blood Cancer Drugs Product Category, Application and Specification
3.2.3 AstraZeneca PLC, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.2.4 Main Business Overview
3.3 Astellas Pharma,
3.3.1 Company Basic Information, Manufacturing Base and Competitors
3.3.2 Blood Cancer Drugs Product Category, Application and Specification
3.3.3 Astellas Pharma, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.3.4 Main Business Overview
3.4 Bayer AG,
3.4.1 Company Basic Information, Manufacturing Base and Competitors
3.4.2 Blood Cancer Drugs Product Category, Application and Specification
3.4.3 Bayer AG, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.4.4 Main Business Overview
3.5 Bristol-Myers Squibb Company,
3.5.1 Company Basic Information, Manufacturing Base and Competitors
3.5.2 Blood Cancer Drugs Product Category, Application and Specification
3.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.5.4 Main Business Overview
3.6 Celgene Corporation,
3.6.1 Company Basic Information, Manufacturing Base and Competitors
3.6.2 Blood Cancer Drugs Product Category, Application and Specification
3.6.3 Celgene Corporation, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.6.4 Main Business Overview
3.7 Eli Lilly,
3.7.1 Company Basic Information, Manufacturing Base and Competitors
3.7.2 Blood Cancer Drugs Product Category, Application and Specification
3.7.3 Eli Lilly, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.7.4 Main Business Overview
3.8 F.Hoffmann-La Roche,
3.8.1 Company Basic Information, Manufacturing Base and Competitors
3.8.2 Blood Cancer Drugs Product Category, Application and Specification
3.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.8.4 Main Business Overview
3.9 Johnson & Johnson,
3.9.1 Company Basic Information, Manufacturing Base and Competitors
3.9.2 Blood Cancer Drugs Product Category, Application and Specification
3.9.3 Johnson & Johnson, Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.9.4 Main Business Overview
3.10 Novartis
3.10.1 Company Basic Information, Manufacturing Base and Competitors
3.10.2 Blood Cancer Drugs Product Category, Application and Specification
3.10.3 Novartis Blood Cancer Drugs Sales, Revenue, Price and Gross Margin(2014-2019)
3.10.4 Main Business Overview
3.11 Pfizer,
3.12 Takeda Pharmaceutical Company Ltd,
3.13 AbbVie
4 Blood Cancer Drugs Market Status and Outlook by Regions
4.1 Global Market Status and Outlook by Regions
4.1.1 Global Blood Cancer Drugs Market Size and CAGR by Regions
4.1.2 North America
4.1.3 Asia-Pacific
4.1.4 Europe
4.1.5 South America
4.1.6 Middle East and Africa
4.2 Global Blood Cancer Drugs Sales and Revenue by Regions
4.2.1 Global Blood Cancer Drugs Sales and Market Share by Regions (2014-2019)
4.2.2 Global Blood Cancer Drugs Revenue and Market Share by Regions (2014-2019)
4.2.3 Global Blood Cancer Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
4.3 North America Blood Cancer Drugs Sales, Revenue, Price and Gross Margin
4.3.1 United States
4.3.2 Canada
4.3.3 Mexico
4.4 Europe Blood Cancer Drugs Sales, Revenue, Price and Gross Margin
4.4.1 Germany
4.4.2 UK
4.4.3 France
4.4.4 Italy
4.4.5 Russia
4.4.6 Turkey
4.5 Asia-Pacific Blood Cancer Drugs Sales, Revenue, Price and Gross Margin
4.5.1 China
4.5.2 Japan
4.5.3 Korea
4.5.4 Southeast Asia
4.5.4.1 Indonesia
4.5.4.2 Thailand
4.5.4.3 Malaysia
4.5.4.4 Philippines
4.5.4.5 Vietnam
4.5.5 India
4.5.6 Australia
4.6 South America Blood Cancer Drugs Sales, Revenue, Price and Gross Margin
4.6.1 Brazil
4.7 Middle East and Africa Blood Cancer Drugs Sales, Revenue, Price and Gross Margin
4.7.1 Egypt
4.7.2 GCC Countries
5 Blood Cancer Drugs Application/End Users
5.1 Blood Cancer Drugs Segment by Application
5.1.1 Leukemia
5.1.2 lymphoma
5.1.3 Multiple Myeloma
5.2 Global Blood Cancer Drugs Product Segment by Application
5.2.1 Global Blood Cancer Drugs Sales by Application
5.2.2 Global Blood Cancer Drugs Sales and Market Share by Application (2014-2019)
6 Global Blood Cancer Drugs Market Forecast
6.1 Global Blood Cancer Drugs Sales, Revenue Forecast (2019-2025)
6.1.1 Global Blood Cancer Drugs Sales and Growth Rate Forecast (2019-2025)
6.1.1 Global Blood Cancer Drugs Revenue and Growth Rate Forecast (2019-2025)
6.2 Global Blood Cancer Drugs Forecast by Regions
6.2.1 North America Blood Cancer Drugs Sales and Revenue Forecast (2019-2025)
6.2.2 Europe Blood Cancer Drugs Sales and Revenue Forecast (2019-2025)
6.2.3 Asia-Pacific Blood Cancer Drugs Sales and Revenue Forecast (2019-2025)
6.2.3.1 China
6.2.3.2 Japan
6.2.3.3 Korea
6.2.3.4 Southeast Asia
6.2.3.5 India
6.2.3.6 Australia
6.2.4 South America Blood Cancer Drugs Sales and Revenue Forecast (2019-2025)
6.2.5 Middle East and Africa Blood Cancer Drugs Sales and Revenue Forecast (2019-2025)
6.2.5.1 Egypt
6.2.5.2 GCC Countries
6.3 Blood Cancer Drugs Forecast by Type
6.3.1 Global Blood Cancer Drugs Sales and Revenue Forecast by Type (2019-2025)
6.3.2 Blood Chemotherapy Drugs Gowth Forecast
6.3.3 Blood Targeted Therapy Drugs Gowth Forecast
6.4 Blood Cancer Drugs Forecast by Application
6.4.1 Global Blood Cancer Drugs Sales Forecast by Application (2019-2025)
6.4.2 Global Blood Cancer Drugs Forecast in Leukemia
6.4.3 Global Blood Cancer Drugs Forecast in lymphoma
7 Blood Cancer Drugs Upstream Raw Materials
7.1 Blood Cancer Drugs Key Raw Materials
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price
7.1.3 Raw Materials Key Suppliers
7.2 Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Blood Cancer Drugs Industrial Chain Analysis
8 Marketing Strategy Analysis, Distributors
8.1 Marketing Channel
8.1.1 Direct Marketing
8.1.2 Indirect Marketing
8.1.3 Marketing Channel Development Trend
8.2 Distributors
8.3 Downstream Customers
9 Research Findings and Conclusion
Appendix
Methodology/Research Approach
Research Programs/Design
Market Size Estimation
Market Breakdown and Data Triangulation
Data Source
Secondary Sources
Primary Sources
Disclaimer